, /PRNewswire/ -- , a global artificial intelligence (AI) digital health company and leader in real-world applications for AI Eye ScreeningTM and AI Predictive BiomarkersTM, today announced the appointment of as Chief Executive Officer. With over 25 years of experience founding and leading healthcare technology enterprises, Haardt takes the helm at Eyenuk to guide the Company into a new era. , previously Eyenuk's interim CEO, will continue to serve the Company as Chief Commercial Officer, his role before taking the interim job.
"I'm deeply honored to join Eyenuk and lead the next phase of our journey to ensure timely diagnosis of vision-threatening and life-threatening diseases through the Company's solutions," said Haardt. Eyenuk's flagship EyeArt® AI eye screening system is the only autonomous AI solution to be both FDA-cleared in the U.S.
for the detection of diabetic retinopathy (DR) and CE-marked under the EU MDR for the detection of DR as well as age-related macular degeneration and glaucomatous optic nerve damage. Providers across the U.S.
and in 26 other countries have used the EyeArt AI system to screen over 300,000 patients since 2020. "On behalf of the Board of Directors, we are excited to welcome Bryan and believe he is the ideal operating leader to shepherd Eyenuk into its next stage of commercial growth," said Eyenuk Executive Chairman . "Bryan's track record of execution and value creation as an entrepreneur, product innovator and executive leader will be inva.
